Our results suggest the prognostic value of SNRPD1 but not SNRPE on breast cancer survival, and warrant the use of SNPRD1 in the onco-therapeutic design given its unveiled roles in sensitizing TNBC cells to anthracycline-type of chemotherapies. The gene discussed is SNRPD1; the disease is breast carcinoma.